Degrading CK1δ to Disarm 'Undruggable' NRAS-Mutant Melanoma
- Targets CK1δ, an upstream kinase that stabilizes oncogenic NRAS mutant protein, as an indirect strategy against NRAS-driven melanoma.
- Reports discovery of compound 8u, a selective small-molecule degrader rather than a simple catalytic inhibitor.
- The degrader approach achieves high selectivity for CK1δ over closely related CK1 isoforms, addressing a limitation of earlier inhibitors.
- Treatment destabilizes mutant NRAS protein and suppresses oncogenic signaling in melanoma models.
💡 Points
Smarter to go after 'undruggable' mutant NRAS through the kinase that stabilizes it than to keep chasing the mutant protein directly, and a degrader — not a catalytic inhibitor — is what finally buys the CK1 paralog selectivity this target class has chronically lacked. Compound 8u reads like a real template, not just a tool compound to prove the hypothesis.